U-47700
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
U-47700 — Pink, U4 — is a synthetic opioid of the benzamide class. It is 7.5 to 12 times more potent than morphine, derived from a structurally unrelated benzamide scaffold.[1] U-47700 is a full agonist at µ-opioid receptors, producing its effects by suppressing pain signaling and depressing respiratory drive.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, heroin, fentanyl +4 moremorphine, heroin, fentanyl, oxycodone, methadone, buprenorphine, all opioids show less
Synthesized by Jacob Szmuszkovicz at The Upjohn Company in 1978 as part of a search for selective opioid analgesics, U-47700 was never developed for clinical use.[3][4] It surfaced on research chemical markets in 2015 and was rapidly linked to hundreds of overdose deaths, including the 2016 death of the musician Prince. Emergency scheduling in the United States followed in late 2016, with international control under the 1961 Single Convention by March 2017.
Subjective effects include euphoria, analgesia, sedation, and anxiolysis. The experience is a compressed opioid arc — a rapid rush of warmth and pain dissolution that fades within hours, driving an intense compulsive redosing urge rarely seen with longer-acting opioids. Nausea, respiratory slowing, and cognitive dulling are characteristic unsought effects.
U-47700 produces rapid physical dependence, and fatal blood concentrations begin as low as 17 ng/mL[5] — one of the narrowest therapeutic margins documented in the opioid class. The majority of documented fatalities involved combination with other depressants, particularly benzodiazepines and fentanyl, which compound respiratory depression beyond what either substance produces alone.[6] No controlled human studies have been conducted; the evidence base rests entirely on animal pharmacology, forensic case series, and computational modeling.
History[edit]
Discovery
U-47700 was synthesized by Jacob Szmuszkovicz at The Upjohn Company in Kalamazoo, Michigan, as part of a systematic program to develop selective mu-opioid receptor agonists from benzamide scaffolds.[3] The compound was first disclosed in US Patent 4,098,904, granted in 1978. Despite demonstrating potent analgesia in animal models, U-47700 was never advanced into clinical development and saw no pharmaceutical or clinical use.[4]
Emergence and crisis
U-47700 remained obscure for nearly four decades until it appeared on a Finnish internet drug forum in March 2015.[7] Its high potency and ease of synthesis made it attractive to research chemical vendors, and by 2016 it circulated widely across North America and Europe under street names including "Pink" and "U4".[4][8] It was also identified in counterfeit oxycodone tablets and in the polydrug mixture known as "gray death",[4] and was detected at the autopsy of the musician Prince in April 2016 alongside fentanyl.
Scheduling
The concentrated wave of fatalities prompted unusually rapid regulatory action. The US DEA cited at least 46 confirmed deaths as the basis for emergency Schedule I placement in November 2016,[9][10] with permanent scheduling following in April 2018. The United Nations placed U-47700 under Schedule I of the 1961 Single Convention in March 2017,[11] and multiple countries — including the United Kingdom, Canada, and Finland — enacted national controls within the same period.
Chemistry[edit]
Structural class
U-47700 belongs to the benzamide structural class — defined by an amide bond linking a substituted benzoyl group to a cycloaliphatic amine. This scaffold was developed at The Upjohn Company as an alternative to morphinan and phenylpiperidine opioids, aiming to achieve μ-opioid selectivity through a structurally distinct framework.[4] Related compounds include AH-7921 (a benzamide opioid that preceded U-47700 on illicit markets) and U-50488 (a selective κ-opioid agonist from the same program).
Molecular structure
| Molecular formula | C₁₆H₂₂Cl₂N₂O |
| Molecular weight | 329.3 g/mol |
The molecule consists of a 3,4-dichlorobenzamide moiety linked through an amide bond to a trans-2-(dimethylamino)cyclohexyl group, with an additional N-methyl substituent on the amide nitrogen.[11] The two chlorine atoms at the 3- and 4-positions of the benzene ring contribute to the compound's lipophilicity and are essential for high mu-opioid binding affinity.
Structure-activity relationships
The 3,4-dichloro substitution pattern on the benzamide ring is critical for potency. Sequential removal of N-methyl groups from the cyclohexylamine nitrogen dramatically reduces receptor binding: the first demethylation (N-desmethyl-U-47700) drops affinity roughly 18-fold, and the second (N,N-didesmethyl-U-47700) renders the compound essentially inactive.[1]
Stereochemistry
U-47700 has two chirality centers on the cyclohexane ring, producing four possible stereoisomers. The pharmacologically active form is the trans diastereomer. A nomenclature discrepancy exists in the literature: some sources designate the active enantiomer as (1S,2S), others as (1R,2R)[4][12] — both describe the same trans isomer, and the difference likely reflects differing priority assignments rather than reference to different molecules. The enantiomeric composition of illicit samples has not been systematically studied. citation needed
Physical properties
U-47700 appears as a white to off-white crystalline powder.[13] No published data on melting point, aqueous solubility, or storage stability were identified. The compound's lipophilicity — conferred by its dichloro aromatic ring and tertiary amine — contributes to rapid brain penetration, which helps explain why its potency in living animals (7.5–12 times morphine) exceeds what its receptor binding affinity alone would predict.[1]
Pharmacology[edit]
Mechanism of action
U-47700 activates the μ-opioid as a full agonist, engaging the same signaling pathway as morphine, heroin, and fentanyl.[8][14] Receptor activation inhibits neuronal firing and reduces neurotransmitter release at pain-transmitting synapses, producing the full spectrum of classical opioid effects: analgesia, euphoria, sedation, respiratory depression, constipation, and pupil constriction.
Full agonist status has been confirmed in laboratory assays, where U-47700 produces maximal receptor activation comparable to reference opioids like fentanyl.[2] All effects are completely reversed by naloxone in both animal models and the single published human clinical case.[2][15]
U-47700 shows strong selectivity for the mu-opioid receptor over kappa and delta subtypes,[1] meaning its effects are overwhelmingly mu-mediated — consistent with the classical opioid profile of analgesia, euphoria, and respiratory depression rather than the dysphoric or psychotomimetic effects associated with kappa activation.
Pharmacokinetics
No controlled human pharmacokinetic studies have been published. In rats, peak blood levels are reached within 15–38 minutes after injection.[1] A computational model using human liver tissue data predicted rapid systemic clearance in humans,[16] consistent with the short duration of action reported by users.
The body breaks down U-47700 primarily by removing its methyl groups in sequence, producing N-desmethyl-U-47700 (the primary metabolite) and then N,N-didesmethyl-U-47700.[17] The primary metabolite retains some opioid activity and may contribute to the overall effect profile.[1]
N-desmethyl-U-47700 is the main marker found in urine during forensic testing and is often present at higher concentrations than the parent compound.[18][17] Standard opioid urine screens do not detect U-47700 — specialized mass spectrometry methods are required.[5][19]
Neuroscience[edit]
Where it acts
U-47700 activates mu-opioid receptors concentrated in two brain systems that together define the opioid experience. In the ventral tegmental area, receptor activation releases dopamine into the nucleus accumbens — the core reward signal underlying euphoria and reinforcement.[8] In the descending pain system, activation in the periaqueductal gray and spinal cord suppresses pain transmission, producing analgesia.[1]
The lethal mechanism — respiratory depression — originates in rhythm-generating neurons of the brainstem that control breathing rate and depth. U-47700's narrow therapeutic index reflects how close the analgesic and respiratory-depressant dose curves sit to each other, a feature it shares with fentanyl and other potent mu-opioid agonists.
Why short duration matters
U-47700's rapid onset and short duration make it a particularly effective driver of compulsive use. Short-acting opioids produce sharp dopamine spikes followed by rapid decline — a pattern that preferentially engages motivational "wanting" circuits over sustained hedonic "liking".[8] Each cycle of rush and fadeout compresses the opponent-process dynamic (pleasure followed by rebound effect discomfort), accelerating psychological dependence relative to longer-acting opioids like methadone or morphine.
Several fundamental questions about U-47700 remain unanswered. Whether it shows biased signaling at the mu-opioid receptor — favoring one intracellular pathway over another — has direct implications for its safety profile but has not been tested.
Subjective Effects[edit]
The U-47700 experience is shaped by compression: a potent μ-opioid effect set packed into a timeframe markedly shorter than classical opioids. Insufflation produces a pronounced euphoric rush — often compared to heroin in initial intensity — that transitions rapidly into heavy sedation and bodily warmth before fading. At lower doses, analgesia and anxiolysis predominate with manageable sedation; at higher doses, consciousness narrows to a dull, weighted drift. Set and setting modulate the anxiolytic and social dimensions but do not substantially alter the core pharmacological character.
Relative to morphine, U-47700 produces qualitatively similar effects but in a compressed arc that encourages repeated dosing. Compared to fentanyl, the onset is somewhat less abrupt but the duration is similarly brief, placing U-47700 in the same pharmacokinetic territory that makes short-acting opioids disproportionately reinforcing.
Effect Grid
At 6–8 mg insufflated, the full mu-opioid effect profile is expressed. Euphoria is pronounced — a pervasive warmth and deep contentment that dominates the experience. Anxiety suppression is strong, cognitive euphoria is marked, and thought deceleration produces a characteristic mental stillness. Emotional suppression flattens affective range.
Tactile euphoria and bodily heaviness are prominent. Sedation is significant, with drowsiness or early nodding possible at the upper end. Pupil constriction is marked. Muscle relaxation is noticeable. Constipation and nausea may occur. Respiratory depression is measurable but not typically life-threatening in isolation.
Compulsive redosing urge becomes strong as the 2–3 hour effects window closes. Accurate dosing within this narrow 2 mg range is safety-critical.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Body high · Constipation · Bodily heaviness · Tactile euphoria · Muscle relaxation · Breathing alteration · Nausea · Dizziness · Physical fatigue · Spontaneous body sensations · Excessive sweating · Dry mouth · Tingling / electric sensations · Sexual arousal suppression · Vomiting · Yawning · Bodily dissociation
Muscle relaxation · Breathing alteration · Nausea · Dizziness · Physical fatigue · Spontaneous body sensations · Excessive sweating · Dry mouth · Tingling / electric sensations · Sexual arousal suppression · Vomiting · Yawning · Bodily dissociation
Analysis suppression · Focus suppression · Information processing suppression · Thought deceleration · Language suppression · Motivation suppression · Confusion · Thought disorganization · Memory suppression · Memory fragmentation · Amnesia · Delirium
Thought deceleration · Language suppression · Motivation suppression · Confusion · Thought disorganization · Memory suppression · Memory fragmentation · Delirium
Social disconnection · Depersonalization · Derealization · Cognitive disconnection
Timeline
Initial opioid effects emerge within minutes — faint warmth spreading from nasal passages, subtle mood lift, first hints of anxiety suppression.
Rapid intensification of euphoria, sedation, and analgesia. Pupil constriction becomes visible. Body high and tactile euphoria build noticeably.
Maximum opioid effects — pronounced euphoria, strong sedation, marked analgesia, and significant respiratory depression. Cognitive euphoria and emotional suppression are at their fullest. Nodding may occur at higher doses.
Effects diminish relatively rapidly. Euphoria fades first while sedation lingers. Compulsive redosing urge peaks as the subjective reward recedes.
Residual sedation, mild cognitive slowing, and possible early withdrawal-like dysphoria in repeat users. Craving may persist.
⚠ Do not drive or operate machinery for at least 6 hours after use — residual sedation and impaired reaction time persist beyond subjective offset.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 1.5 weeks
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · fentanyl
Toxicity
Acute toxicity
U-47700 carries high acute toxicity driven by a narrow therapeutic index — the dose that produces respiratory depression sits close to the dose that produces analgesia, leaving minimal margin between effect and death.[4] No formal lethal dose has been established in any species. safety citation needed
Fatal blood concentrations documented in forensic cases span a broad range. The lowest reported fatal concentration is 17 ng/mL,[5] while the highest exceeds 2,000 ng/mL[6] — the wide spread reflects differences in tolerance, co-ingested substances, and postmortem redistribution effects.
The mechanism of death in all documented cases is respiratory depression leading to oxygen deprivation and cardiac arrest — the same mechanism responsible for all μ-opioid overdose deaths.
Fatality epidemiology
Documented deaths are concentrated in the 2016–2017 period, before international scheduling took effect. German forensic data identified 26 fatalities (25 male, mean age 34), with over half involving co-use of other novel psychoactive substances.[6] US CDC surveillance found U-47700 in 40 opioid overdose deaths across 10 states in the second half of 2016 — 60% of those cases also tested positive for fentanyl.[20]
Finnish authorities confirmed 10 fatalities,[7] and at least 46 US deaths were cited as the basis for emergency scheduling.[9] Canadian polysubstance fatalities included co-detection with furanylfentanyl.[21] The overwhelming majority of deaths involved combination with other depressants.[6][7]
Selected case reports
Key forensic and clinical cases illustrate the compound's risk profile. One fatality involved insufflation with co-detected alprazolam, attributed to combined toxicity.[22] The first documented intravenous fatality confirmed high-purity powder and provided novel tissue distribution data.[13] A multi-drug death combined U-47700 with stimulants and designer benzodiazepines.[23]
One individual was revived at the scene but died six days later in intensive care, with co-detected mitragynine.[24] The first published near-fatal clinical case confirmed that naloxone reversed the opioid toxidrome.[15]
Detection limitations
U-47700 is invisible to standard hospital and forensic drug screens designed for morphine, codeine, or fentanyl. Identification requires specialized mass spectrometry methods.[5][19][25] This limitation contributed to under-detection during the initial wave of fatalities and remains a harm-amplification factor wherever U-47700 may be present.
Naloxone reversibility
U-47700's effects are fully reversible by naloxone. In the first published near-fatal case, naloxone administration restored breathing and consciousness.[15] In animal models, all effects were completely naloxone-reversible.[2] Given U-47700's high potency, standard naloxone doses used for heroin overdose (0.4 mg) may prove insufficient; multiple doses or higher initial doses may be required.[26] Naloxone should be titrated to restoration of adequate breathing, not to full consciousness.
Psychological risks
No controlled studies of U-47700's psychological effects have been conducted. The following risks are expected based on its pharmacological profile as a potent, short-acting full mu-opioid agonist.
The combination of rapid onset, intense euphoria, and short duration creates strong compulsive redosing behavior — consistently described in user reports and reflected in forensic cases where multiple doses preceded death. Full mu-opioid agonism with rapid onset produces strong positive reinforcement, and psychological dependence is expected to develop quickly with repeated use.
At higher doses, cognitive slowing, sedation, and confusion impair decision-making during intoxication, increasing the risk of accidental overdose through continued redosing.
Withdrawal produces significant psychological distress including anxiety, irritability, depression, and intense craving. Given U-47700's short duration, withdrawal symptoms may emerge within hours of last use in dependent individuals.
Tolerance and dependence
U-47700 is expected to produce rapid tolerance through the standard mechanisms shared by all full mu-opioid agonists: receptor desensitization, internalization, and downstream adaptation in brain reward and stress circuits. No published tolerance studies specific to U-47700 exist. inferred
Cross-tolerance with all other opioids — morphine, heroin, fentanyl, oxycodone — is expected given the shared receptor mechanism.[8] Physical dependence producing a characteristic opioid withdrawal syndrome (autonomic hyperactivity, gastrointestinal distress, musculoskeletal pain, insomnia, intense craving) is expected with prolonged use. Given U-47700's short duration, withdrawal onset may be more rapid than with longer-acting opioids.
U-47700's high euphoric potency, rapid onset, and short duration produce a pharmacokinetic profile with high addiction liability. Standard opioid agonist therapy (buprenorphine, methadone) and antagonist therapy (naltrexone) would theoretically apply, but no published case reports document their use in U-47700-dependent individuals specifically. inferred
Drug interactions
The majority of U-47700 fatalities involved polysubstance use. Combination with any central nervous system depressant carries risk of fatal respiratory depression. No specific interaction studies exist; all assessments derive from published case reports and pharmacological class inference.
Additive respiratory depression
- Benzodiazepines: Multiple fatal cases document co-ingestion of both designer benzodiazepines (flubromazolam, diclazepam) and classical benzodiazepines (alprazolam) with U-47700.[23][22] This combination is documented as directly lethal.
- Alcohol: Produces additive respiratory and central nervous system depression. Lethal interaction severity is consistent with opioid-alcohol pharmacology.
- GHB/GBL: Both are potent depressants that compound respiratory depression when combined with opioids.
- Other opioids: Additive mu-opioid activation compounds respiratory depression. Tramadol additionally carries seizure risk in combination.
Metabolic interactions
U-47700 is metabolized primarily by CYP3A4. Strong inhibitors of this enzyme (ketoconazole, clarithromycin, ritonavir) could substantially increase U-47700 blood levels, effectively raising the delivered dose. Enzyme inducers (rifampicin, carbamazepine) could reduce levels, potentially precipitating withdrawal in dependent individuals. inferred
Dissociative combinations
Ketamine produces respiratory depression at anesthetic doses; combination with opioids increases this risk. The interaction between U-47700 and PCP has not been characterized. citation needed
Contraindications
No formal contraindication studies specific to U-47700 have been conducted. The following are inferred from its pharmacological profile: inferred
- Respiratory compromise: Pre-existing breathing impairment (chronic obstructive pulmonary disease, asthma, sleep apnea) dramatically lowers the fatal dose threshold.
- Concurrent depressant use: Co-administration with benzodiazepines, alcohol, barbiturates, GHB/GBL, or other opioids is contraindicated based on documented fatality data.
- Liver impairment: Reduced metabolic clearance would increase drug exposure and overdose risk.
- Opioid-naive individuals: The narrow therapeutic index makes U-47700 exceptionally dangerous in people without opioid tolerance. Fatal blood levels as low as 17 ng/mL have been documented.[5]
- Pregnancy: All mu-opioid agonists carry risk of neonatal opioid withdrawal syndrome. No U-47700-specific reproductive data exist. safety citation needed
- CYP3A4 inhibitor co-administration: Concurrent use of potent CYP3A4 inhibitors increases blood levels and overdose risk.
Harm Reduction[edit]
Forms & Identification
U-47700 is not detected by standard immunoassay drug screens or fentanyl test strips — a negative result on either test does not confirm the absence of this compound. The only reliable identification method is laboratory mass spectrometry, which is unavailable to most users.
Because U-47700 has appeared in counterfeit pharmaceutical tablets[4] and polysubstance mixtures like "gray death," any unregulated opioid powder or pressed pill could contain it. Reagent testing can help distinguish broad substance classes but cannot reliably identify or quantify U-47700 specifically. The practical implication is that dose precision is uncertain with any illicit sample, and the narrow margin between an active and fatal dose makes this uncertainty especially dangerous.
Guidelines
- Test every sample with available reagent kits, understanding their limitations for this compound.
- Weigh doses with a milligram-scale balance. Never estimate by eye.
- Use volumetric dosing (dissolving a weighed amount in a measured volume of liquid) to reduce hotspot risk in powder.
- Start with the lowest reported threshold dose, especially if opioid-naive or tolerance status is uncertain.
- Set a firm redosing limit before the session. The compulsive compulsive redosing urge is the defining behavioral risk.
- Always have naloxone immediately accessible — and ensure the observer knows how to administer it.
- Never combine with benzodiazepines, alcohol, other opioids, or any central nervous system depressant.
- Never use alone.
Set & Setting
U-47700's short duration and intense rush drive compulsive redosing. Using in isolation removes the only safeguard against overdose if consciousness is lost. A sober observer with access to naloxone is the single most effective harm reduction measure for this compound.
The environment should allow the user to lie in the recovery position if sedation becomes heavy. Avoid settings where loss of consciousness could result in injury — near water, at height, or while operating machinery.
Aftercare & integration. After any U-47700 session, monitor for delayed respiratory depression — especially if multiple doses were taken or other depressants were co-ingested. At least one documented fatality occurred six days after initial resuscitation.[24]
Hydrate, eat when appetite returns, and prioritize sleep. If the session involved compulsive redosing, treat that pattern as a signal: short-acting opioids produce escalating psychological dependence with each compressed use cycle. Honest self-assessment of redosing behavior is more useful than post-hoc rationalization.
If use was motivated by chronic pain or emotional distress, explore non-opioid alternatives with a healthcare provider before the next exposure.
Recovery & Support
U-47700 dependence is pharmacologically identical to other opioid dependencies and responds to the same evidence-based treatments. Opioid agonist therapy (buprenorphine or methadone) stabilizes the μ-opioid system and reduces craving. Naltrexone (an opioid antagonist) blocks receptor activation and is an option after full detoxification.
Given U-47700's short duration, withdrawal onset may be rapid — within hours of last use. Medical supervision during withdrawal reduces both suffering and the risk of relapse-driven overdose, which is highest in the days immediately following cessation when tolerance has dropped but craving has not.
Peer support programs and addiction counseling complement pharmacotherapy. No U-47700-specific treatment protocols exist, but standard opioid use disorder treatment pathways apply.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
The signs of U-47700 overdose are identical to other opioid overdoses: breathing slows or stops, lips and fingertips turn blue or gray, the person becomes unresponsive, and pupils constrict to pinpoints. Loud snoring or gurgling in an unconscious person indicates airway obstruction and imminent respiratory failure.
Immediate steps
- 1. Call emergency services immediately.
- 2. Administer naloxone if available. Standard doses (0.4 mg) may be insufficient for U-47700 — administer additional doses every 2–3 minutes if breathing does not improve.[26]
- 3. Place the person in the recovery position (on their side) to prevent aspiration.
- 4. Stay with them. U-47700's duration may outlast naloxone, and breathing can stop again.
- 5. Do not induce vomiting. Do not leave the person alone.
What to tell the dispatcher
State that the person is not breathing or breathing very slowly, that you suspect opioid overdose, the substance name if known, the approximate time of last dose, and whether naloxone has been given. Good Samaritan laws in many jurisdictions protect callers who report overdoses from drug-related prosecution.
Reversal agent
Naloxone reverses U-47700 overdose.[15][2] Multiple doses may be necessary. Titrate to adequate breathing, not full consciousness — waking an opioid-dependent person too abruptly can precipitate severe withdrawal.
Legal Status[edit]
U-47700 is internationally controlled under Schedule I of the 1961 Single Convention on Narcotic Drugs, placed at the 60th session of the UN Commission on Narcotic Drugs in March 2017.[11] The speed of international scheduling — from first market detection in 2015 to Single Convention control in 2017 — was unusually rapid, driven by the concentrated wave of fatalities across multiple countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency placement November 14, 2016; permanent Schedule I April 20, 2018. At least 46 confirmed deaths cited as basis for emergency action.[10][9] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the 2017 Amendment Order, effective May 31, 2017.[27] |
| International | Schedule I (1961 Single Convention) | Placed at the 60th session of the UNCND, March 2017.[11] |
| Canada | Schedule I (CDSA) | Added to Schedule I of the Controlled Drugs and Substances Act, December 2017.[28] |
| Finland | National control | Nationally controlled from November 2016.[7] |
| Germany | Anlage I (BtMG) | Controlled under the Narcotics Act (Betaeubungsmittelgesetz), circa 2016. citation needed |
| New Zealand | Class A (Misuse of Drugs Act 1975) | Classified December 2022. citation needed |
Prior to its specific scheduling in the United States (November 2016), U-47700 may have been subject to the Federal Analogue Act based on structural and pharmacological similarity to controlled opioids, though no published case law testing this application was identified.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abcdFels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwaerter V, Musshoff F (2019) Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug — Forensic Science International doi:10.1016/j.forsciint.2019.04.010